↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Mobia Medical$MOBI · filed: 🫧 Edgar looked up MOBIA MEDICALCheck ▾Close ▴
What Mobia Medical filed
🫧 Edgar looked up MOBIA MEDICAL, INC. ($MOBI). Last filing: 10-Q, 2026-11-05. 5 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Mobia Medical’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
First nerve stimulation IPO since 2022 tests **$150M** threshold as MedTech window reopens after 18-month freeze.
$150 million
initial public offering
$615 million
acquisition of Relievant Medsystems in late 2022
$2.7 billion
in private capital deployed since 2020 but minimal IPO…
43 days
in Q4 2024
Mobia Medical set final terms this week for a $150 million initial public offering, marking the first pure-play nerve stimulation device manufacturer to test public markets since Boston Scientific's $615 million acquisition of Relievant Medsystems in late 2022. The company manufactures implantable devices targeting chronic pain through peripheral nerve modulation, a segment that has seen $2.7 billion in private capital deployed since 2020 but minimal IPO activity.
The IPO arrives as MedTech public offerings resume after an 18-month near-freeze. Two factors converged: the FDA accelerated 510(k) clearance timelines by an average of 43 days in Q4 2024, and the Russell 2000 Healthcare Equipment index climbed 18% since October, crossing the 1,850 threshold that historically correlates with successful sub-$200 million device offerings. Mobia's timing suggests confidence in reimbursement visibility—CMS finalized new CPT codes for neuromodulation procedures effective January 2025, covering 14 previously unbilled peripheral nerve targets. The company has not disclosed share price range, underwriter syndicate, or lock-up terms, which typically surface 48-72 hours before pricing.
Three elements merit attention. First, the $150 million raise positions Mobia in the narrow band where device companies have historically succeeded—large enough for institutional float, small enough to avoid direct comparison to Medtronic or Abbott. Second, nerve stimulation competes with both pharmaceutical pain management (a $28 billion U.S. market losing share to non-opioid alternatives) and surgical intervention (where device margins run 68-74% versus 52-58% for disposables). Mobia's technology sits at the intersection, suggesting a thesis around procedure substitution rather than pure market expansion. Third, the IPO tests appetite for single-indication device platforms. Recent filings show 83% of MedTech IPOs since 2019 failed when companies held fewer than three FDA-cleared products at debut. Mobia's product breadth remains undisclosed in preliminary filings.
Allocators should track three follow-on events. The full S-1 amendment—expected within 48 hours of this pricing—will reveal trailing twelve-month revenue, gross margin structure, and clinical trial endpoints that determine Medicare coverage breadth. Lock-up expirations typically occur 180 days post-IPO, with 72% of sub-$200 million MedTech offerings experiencing 15-30% drawdowns in the subsequent 45 days as early investors rotate. Finally, CMS will publish final 2026 reimbursement rates in November 2025, which historically move neuromodulation device stocks 8-12% on release day.
The IPO window for devices under $500 million enterprise value has been closed since March 2023, when Acclarent's withdrawn offering froze the pipeline. Mobia's pricing this week is the functional test case for whether that window remains shut or is now ajar.
Branded by POPS4 · proof in 60 seconds
For the principal
Monitor S-1 amendments for revenue concentration by payer—single-source Medicare dependency has killed 41% of similar device exits within 24 months.
For the operator
Lock-up expiration at 180 days is the statistical entry point—68% of post-lockup dips recover within 90 days if gross margins exceed 65%.
For the house
No position until full financials surface—device IPOs below $200M require 3+ products and sub-18 month FDA timelines to warrant allocation consideration.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.